TNBC, defined by the lack of estrogen and progesterone receptors and HER2, accounts for 15–20% of all breast cancer subtypes and typically display aggressive behavior, including early recurrence and metastasis, despite intensive chemotherapy treatment [34]. This evidence concerns the gene ERBB2 and breast cancer.